{"gene":"NR2C1","run_date":"2026-04-29T11:37:57","timeline":{"discoveries":[{"year":1989,"finding":"NR2C1 (TR2) was molecularly cloned from human testis cDNA libraries as a new member of the steroid receptor superfamily containing conserved zinc-finger DNA-binding domains; multiple isoforms with distinct ligand-binding domain lengths were identified, and no binding activity with known steroid hormones was found, classifying it as an orphan receptor.","method":"cDNA cloning, in vitro translation, sequence analysis","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 — original cloning paper with in vitro translation and sequence characterization","pmids":["2597158"],"is_preprint":false},{"year":1995,"finding":"TR2 orphan receptor binds hormone response elements containing AGGTCA direct repeat sequences with preference order DR1 > DR2 > DR5 ≥ DR4 > DR6 > DR3, and competes with RXRα and RARα/RXRα heterodimers at CRBPIIp (DR1) and RARβ (DR5) response elements to suppress retinoic acid-stimulated transcription without forming heterodimers with RXRα or RARα.","method":"CAT reporter assays, gel mobility shift assays (EMSA), competition binding","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro DNA binding with Kd measurements plus functional reporter assays","pmids":["8530418"],"is_preprint":false},{"year":1995,"finding":"A natural TR2 response element (TR2RE-SV40) was identified in the SV40 +55 region with high affinity binding (Kd = 9 nM); TR2 binding to this element represses both SV40 early and late promoter transcriptional activities.","method":"EMSA with in vitro translated TR2, CAT reporter assays, DNA-swap experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro binding with Kd measurement plus functional reporter assays with mutagenesis","pmids":["7890658"],"is_preprint":false},{"year":1997,"finding":"The TR2 orphan receptor (TR2-11-f) binds as homodimers to a DR4 hormone response element in the mouse CRABP-I gene promoter (Kd = 2.6 nM) through its ligand-binding domain, and suppresses CRABP-I reporter gene expression.","method":"Gel retardation assay, yeast two-hybrid, CAT reporter assays","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro binding with Kd, dimerization domain mapping, functional reporter assays","pmids":["9369481"],"is_preprint":false},{"year":1997,"finding":"TR2 binds the M1 site in the human aldolase A muscle-specific promoter (Kd = 4.6 nM), induces localized DNA bending (~73°), and functions as a transcriptional inducer of aldolase A expression in muscle cells.","method":"EMSA, circular permutation assay, dual-luciferase reporter assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 — in vitro binding with Kd and bend angle; single lab","pmids":["9196064"],"is_preprint":false},{"year":1997,"finding":"Two TR2 isoforms (TR2-11 and truncated TR2-11-t lacking the ligand-binding domain) have opposing biological activities: TR2-11 represses RA induction via a DR5-type RARE and binds DNA as dimers, whereas TR2-11-t enhances RA induction and cannot bind DNA; the full-length LBD is required for DNA binding and repression.","method":"CAT reporter assays, gel-shift assays, prokaryotic expression, isoform characterization","journal":"The Journal of endocrinology","confidence":"High","confidence_rationale":"Tier 1 — direct functional comparison of isoforms with DNA binding and reporter assays","pmids":["9071982"],"is_preprint":false},{"year":1998,"finding":"Mouse RIP140 was identified as a corepressor for TR2; RIP140 interacts with TR2 through LXXLL motifs binding to the C-terminal AF-2 region of TR2's LBD; in the presence of RIP140, cytosolic GFP-tagged TR2 LBD translocates to the nucleus; RIP140 represses TR2-mediated and RA receptor-mediated transcription in reporter assays.","method":"Yeast two-hybrid, coimmunoprecipitation, GFP localization, GAL4 reporter assays, domain mapping","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — yeast two-hybrid + in vivo coIP + GFP localization + functional reporter, multiple orthogonal methods","pmids":["9774688"],"is_preprint":false},{"year":1998,"finding":"TR2 and TR4 preferentially form heterodimers in solution and on DR5 DNA elements; heterodimerization is mediated by the ligand-binding domains, with three leucine residues on helix 10 of TR2 critical for interaction; TR2/TR4 coexpression exerts stronger repression on a DR5 reporter than either receptor alone.","method":"Yeast two-hybrid, mammalian two-hybrid, pull-down assay, EMSA, GFP colocalization, reporter assays, domain mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including pulldown, two-hybrid, EMSA, live-cell imaging, and mutagenesis","pmids":["9737983"],"is_preprint":false},{"year":1998,"finding":"TR2 repressor activity requires high-affinity DNA binding, receptor dimerization, and an active silencing domain (DEF segment); a transferable trans-repressive activity resides in the DEF segment including C-terminal 49 amino acids; point mutations at three conserved leucines on the predicted dimer interface abolish suppressive activity, dimerization, and DNA binding.","method":"GAL4 reporter assays, deletion and point mutagenesis, functional domain mapping","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis with multiple functional readouts","pmids":["9660764"],"is_preprint":false},{"year":1998,"finding":"TR2 bidirectionally interacts with the CNTF signaling pathway: CNTF induces TR2 expression, and TR2 in turn activates CNTFRα transcription through a direct repeat response element (AGGTCA) in the CNTFRα intron 5; TR2 and CNTFRα show overlapping expression in developing neural structures.","method":"Reporter assays (CAT), RT-PCR, in situ hybridization, DNA binding assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — functional reporter + expression studies; single lab","pmids":["9694834"],"is_preprint":false},{"year":1998,"finding":"TR2 is exclusively localized to the nucleus via a constitutive nuclear localization signal comprising 20 amino acids (KDCVINKHHRNRCQYCRLQR) within the second zinc-finger of the DNA-binding domain; no NLS activity was found in the N-terminus or LBD; nuclear-localized GFP-TR2 retains repressive activity on DR5 reporters.","method":"GFP fusion live-cell imaging, HA-antibody detection, deletion analysis, EMSA","journal":"The Journal of endocrinology","confidence":"High","confidence_rationale":"Tier 2 — live-cell GFP imaging + deletion mapping + functional validation","pmids":["9795341"],"is_preprint":false},{"year":1998,"finding":"TR2 shows transactivation via a DR4-TRE element and competes with unliganded TRα1/RXRα heterodimer; TR2 cancels the suppressive effect of unliganded TRα1 on CAT reporter activity in a dose-dependent, DNA-binding–dependent manner.","method":"EMSA, CAT reporter assays, competition binding","journal":"Molecular and cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 1-2 — binding and functional assays; single lab, single study","pmids":["9879671"],"is_preprint":false},{"year":1996,"finding":"Ionizing radiation represses TR2 expression at both transcriptional and translational levels; p53 (endogenously induced or exogenously transfected) represses TR2 gene expression, and this repression is reversed by SV40 large T antigen co-transfection, placing p53 upstream of TR2 in the radiation response.","method":"Transient transfection, CAT reporter assays, Northern blot, radiation treatment","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis by gain/loss of p53 plus reporter assays; single lab","pmids":["8663350"],"is_preprint":false},{"year":1999,"finding":"An IR0-type retinoic acid response element in the TR2-11 gene proximal promoter is bound specifically by RARα/RXRβ heterodimers (Kd ~8 nM) but not by either receptor alone; this element mediates RA-induced transcription of the TR2-11 gene.","method":"EMSA, reporter assays, gel mobility shift with nuclear extracts","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 1 — in vitro binding with Kd determination plus functional reporter; single lab","pmids":["10393558"],"is_preprint":false},{"year":2000,"finding":"TR2 constitutively activates endogenous RARβ2 gene expression in P19 cells via the DR5 element in the RARβ2 promoter; cAMP enhances this activation via the CRE; the constitutive activation function (AF-1) maps to residues 10–30 in the N-terminal A segment; TR2 and CREMτ directly interact (co-IP) via the TR2 N-terminal AB segment.","method":"Reporter assays, EMSA competition, coimmunoprecipitation, domain mapping, Northern blot","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple methods: functional reporter + EMSA + co-IP + domain mapping","pmids":["10766818"],"is_preprint":false},{"year":2001,"finding":"TR2 directly interacts with class I (HDAC3) and class II (HDAC4) histone deacetylases; the DNA-binding domain of TR2 mediates the interaction with both HDACs (not the LBD); TR2-HDAC complexes exhibit deacetylase activity in vitro; HDAC inhibitor trichostatin A relieves TR2-mediated transcriptional repression.","method":"Co-IP with FLAG-tagged HDACs, GST pull-down, far Western blot, deacetylase activity assay, reporter assays with TSA","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro pull-down + co-IP with endogenous proteins + deacetylase activity assay + functional rescue","pmids":["11463856"],"is_preprint":false},{"year":2002,"finding":"TR2 forms a heterodimer with the estrogen receptor (ER) that disrupts ER homodimerization and ER DNA binding, thereby suppressing ER-mediated transcription; an interaction-blocking peptide (ER-6, aa 312–340) reverses this suppression; antisense TR2 in MCF7 cells enhances ER transcriptional activity; TR2-mediated ER suppression inhibits estrogen-induced cell growth and G1/S transition.","method":"GST pull-down, mammalian two-hybrid, CAT reporter assays, antisense knockdown, cell proliferation assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — pulldown + two-hybrid + functional reporter + cell-based loss-of-function; multiple orthogonal methods","pmids":["12093804"],"is_preprint":false},{"year":2002,"finding":"TR2 and TR4 form a heterodimer (DRED complex, ~540 kDa) that binds DR1 sites in the human embryonic ε-globin and fetal γ-globin gene promoters with high affinity; an HPFH mutation in the DR1 site reduces TR2/TR4 binding in vitro; transgenic forced expression of TR2/TR4 reduces endogenous embryonic εy-globin transcription in mice.","method":"Biochemical purification, mass spectrometry, EMSA, EMSA competition with mutant DR1, transgenic mouse expression","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1-2 — complex purification + MS identification + EMSA with Kd + in vivo transgenic validation","pmids":["12093744"],"is_preprint":false},{"year":2003,"finding":"HDAC3 interacts with TR2 through two domains: N-terminal residues 1–135 (specifically 1–70) and C-terminal residues 210–428 (specifically 270–320); these two binding sites compete for TR2; the TR2-HDAC3 complex formed on TR2 DNA target sequences exhibits histone deacetylase activity in vivo.","method":"GST pull-down, coimmunoprecipitation, ChIP, histone deacetylase activity assay, domain mapping","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro pulldown domain mapping + co-IP + ChIP + deacetylase activity assay","pmids":["14521922"],"is_preprint":false},{"year":2003,"finding":"TR2 suppresses androgen receptor (AR)-mediated transactivation and PSA expression in prostate cancer PC-3 cells through direct protein-protein interaction with AR (demonstrated by GST pulldown and mammalian two-hybrid), not by competing for common coregulators.","method":"CAT reporter assays, Northern blot, GST pull-down, mammalian two-hybrid","journal":"The Prostate","confidence":"Medium","confidence_rationale":"Tier 2 — pulldown + two-hybrid + functional assays; single lab","pmids":["12949936"],"is_preprint":false},{"year":2005,"finding":"PKC phosphorylates TR2 at Ser-568 and Ser-461 in the LBD; Ser-568 phosphorylation is required for PKC-mediated enhancement of TR2 protein stability (protection from proteasome-mediated degradation) and transcriptional activation of its target gene RARβ.","method":"In vivo metabolic labeling, kinase/phosphatase inhibitor treatment, LC-ESI-MS/MS, site-directed mutagenesis, reporter assays, proteasome inhibitor experiments","journal":"Proteomics","confidence":"High","confidence_rationale":"Tier 1 — MS-confirmed phosphosites + mutagenesis + functional activity assays","pmids":["16130175"],"is_preprint":false},{"year":2006,"finding":"PKC phosphorylates TR2 at Ser-185 in the DNA-binding domain (confirmed by MS); DBD phosphorylation facilitates TR2 DNA binding and recruitment of coactivator PCAF; Ser-185 is required for DNA binding, and both Ser-170 and Ser-185 are necessary for PCAF interaction; double mutant significantly reduces RARβ2 activation.","method":"LC-ESI-MS/MS, site-directed mutagenesis, EMSA, co-IP, reporter assays","journal":"Proteomics","confidence":"High","confidence_rationale":"Tier 1 — MS phosphosite identification + mutagenesis + EMSA + coIP + functional assays","pmids":["16317770"],"is_preprint":false},{"year":2006,"finding":"TR2 can be SUMOylated at Lys-238; unSUMOylated TR2 localizes to PML nuclear bodies and activates Oct4 (recruiting coactivator PCAF), whereas elevated TR2 abundance triggers SUMOylation, release from PML bodies, and coregulator exchange: PCAF is replaced by corepressor RIP140, converting TR2 from an activator to a repressor of Oct4.","method":"SUMOylation assays, coimmunoprecipitation, GFP live imaging, ChIP, reporter assays, knockdown experiments","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods; Nature structural publication with mechanistic detail","pmids":["17187077"],"is_preprint":false},{"year":2007,"finding":"TR2 is a preadipocyte proliferator that activates c-Myc via an IR0-type RA response element; in preadipocytes RA induces GRIP1/PCAF coactivator complex recruitment to the TR2 promoter (promoting TR2 expression), while in differentiated adipocytes RA induces GRIP1/RIP140 corepressor complex recruitment (repressing TR2); GRIP1 directly interacts with both PCAF and RIP140 and serves as a platform molecule.","method":"siRNA knockdown, reporter assays, ChIP, co-IP, domain mapping, 3T3-L1 cell model","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 — ChIP + co-IP + knockdown + functional assays with multiple coregulators; multiple methods","pmids":["17389641"],"is_preprint":false},{"year":2007,"finding":"TR2/TR4 directly represses GATA1/Gata1 transcription in murine and human erythroid progenitor cells through binding to an evolutionarily conserved DR element within the GATA1 hematopoietic enhancer (G1HE); TR2/TR4 binding was shown by EMSA and ChIP, and mutation of the DR element elevated Gata1 promoter activity and reduced TR2/TR4 responsiveness.","method":"EMSA, ChIP, reporter assays with DR site mutagenesis, transgenic mice, null mutant mice, shRNA knockdown in CD34+ cells","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1-2 — EMSA + ChIP + mutagenesis + in vivo gain/loss-of-function replicated in multiple systems","pmids":["17974920"],"is_preprint":false},{"year":2007,"finding":"TR2/TR4 play critical roles in developmental silencing of embryonic β-type globin genes (εy and γ); TR2 and TR4 null mutant mice show delayed silencing of embryonic and fetal β-globin genes; dominant-negative TR4 activates human ε-globin in both primitive and definitive erythroid cells, but activates γ-globin only in definitive erythroid cells; forced expression of TR2/TR4 causes precocious ε-globin repression.","method":"Knockout mice, transgenic mice (dominant-negative and forced expression), RT-PCR, Southern blot, in situ hybridization","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — genetic gain and loss of function in multiple mouse models, replicated in different genetic backgrounds","pmids":["17431400"],"is_preprint":false},{"year":2008,"finding":"All-trans retinoic acid (atRA) triggers a nongenomic signaling cascade: atRA → MEK/ERK2 complex formation → ERK2 phosphorylates TR2 at Thr-210 → phospho-TR2 associates increasingly with PML nuclear bodies and undergoes SUMOylation → corepressor RIP140 replaces coactivator PCAF → TR2 switches from activator to repressor of Oct4; unphosphorylated TR2 recruits PCAF and activates Oct4.","method":"Phosphorylation assays, site-directed mutagenesis (Thr-210), co-IP, ChIP, confocal microscopy, reporter assays, inhibitor studies (MEK/ERK inhibitors)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods with site-specific mutagenesis and pathway inhibitors","pmids":["18682553"],"is_preprint":false},{"year":2009,"finding":"HDAC3 acts as a molecular chaperone to shuttle phosphorylated TR2 (phospho-Thr-210) to PML nuclear bodies; this chaperone function is independent of HDAC3 deacetylase activity; atRA also stimulates nuclear enrichment of HDAC3 and its complex formation with PML in an ERK2-independent manner.","method":"Co-IP, in vitro binding assays, confocal microscopy, deacetylase-dead HDAC3 mutants, PML recruitment assays","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro and in vivo assays with deacetylase-inactive mutant to separate functions; multiple methods","pmids":["19204783"],"is_preprint":false},{"year":2011,"finding":"TR2 and TR4 recruit multiple epigenetic corepressor complexes (DNMT1, NuRD, LSD1/CoREST, HDAC3, TIF1β) to embryonic β-type globin promoters in differentiated adult erythroid cells; ChIP shows TR2/TR4 bind embryonic but not adult β-globin promoters; upon terminal differentiation, corepressors dissociate selectively from the adult promoter but remain at silenced embryonic promoters.","method":"Biotin-tagged protein complex purification, mass spectrometry, co-IP, ChIP in differentiated vs. undifferentiated erythroid cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 — biochemical purification + MS identification + co-IP + ChIP with developmental stage comparison; replicated with multiple corepressors","pmids":["21670149"],"is_preprint":false},{"year":2015,"finding":"Compound conditional knockout of both Tr2 and Tr4 in adult bone marrow cells induces expression of embryonic εy and βh1 globins; loss of TR2/TR4 abolishes their occupancy on εy and βh1 promoters and impairs co-occupancy by interacting corepressors; TR2/TR4 function is also required for terminal erythroid cell maturation.","method":"Conditional knockout mouse genetics, in vitro bone marrow differentiation, ChIP, RT-PCR, flow cytometry","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — conditional double KO with ChIP showing loss of promoter occupancy and corepressor co-occupancy","pmids":["25561507"],"is_preprint":false},{"year":2017,"finding":"Nr2c1 (Tr2) loss-of-function in mice causes severe vision deficits, disrupts early retinal cell patterning (increased displaced amacrine cells, altered cone photoreceptor topography), and affects early but not late retinal cell types; ChIP experiments show NR2C1 regulates early retinal progenitor transcription factors including Satb2 (amacrine) and cone photoreceptor regulators (thyroid and retinoic acid receptors).","method":"Nr2c1 knockout mouse, electroretinography, histology, ChIP, immunofluorescence","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 — in vivo KO with defined cellular phenotype + ChIP identifying direct target regulators","pmids":["28551284"],"is_preprint":false},{"year":2016,"finding":"Evolutionary analysis and functional assays of human, chimpanzee, and ancestral NR2C1 proteins showed that hominid-specific changes in NR2C1 alter its ability to modulate Oct4 and Nanog transcription (pluripotency regulators), Pepck promoter activity (a differentiation proxy), and embryonic stem cell colony size, indicating NR2C1 underwent adaptive evolution affecting stem cell pluripotency regulation.","method":"Codon evolution analysis, reporter assays, stem cell colony assays, ancestral sequence reconstruction","journal":"Genetics","confidence":"Medium","confidence_rationale":"Tier 2 — functional assays with reconstructed ancestral protein; single study","pmids":["27075724"],"is_preprint":false},{"year":2023,"finding":"In pancreatic cancer, miR-492 acts as an enhancer trigger that activates NR2C1 expression; NR2C1 promotes epithelial-mesenchymal transition (EMT) through the TGF-β/Smad3 signaling pathway; CRISPR-Cas9 and ChIP assays confirmed miR-492 enhancer regulation of NR2C1, and antagomiR-492 suppressed tumorigenesis by downregulating NR2C1.","method":"CRISPR-Cas9, ChIP, in vitro migration/invasion assays, in vivo xenograft, Western blot, knockdown/overexpression","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 — CRISPR + ChIP + in vivo validation; single lab","pmids":["36591938"],"is_preprint":false},{"year":2025,"finding":"TR2 (along with COUP-TF1, COUP-TF2, and TR4) promotes telomeric H3K9me3 and alternative lengthening of telomeres (ALT) by recruiting TRIM28 to telomeres; physical interaction between TR2 and TRIM28 is required for TRIM28 telomeric localization; a TRIM28 variant defective in orphan NR interaction fails to localize to telomeres and cannot promote H3K9me3 or ALT phenotypes.","method":"Co-IP, ChIP, telomere-specific assays (C-circles, APBs), TRIM28 interaction-defective mutant, human fibroblast and ALT cancer cell lines","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP + ChIP + mutant rescue; preprint, single lab","pmids":["bio_10.1101_2025.06.16.658187"],"is_preprint":true}],"current_model":"NR2C1 (TR2) is an orphan nuclear receptor that binds AGGTCA direct repeat elements as homodimers or TR2/TR4 heterodimers to repress or activate target genes (including embryonic/fetal β-globin, GATA1, Oct4, RARβ2, and others) through ligand-independent mechanisms involving post-translational modifications (PKC-mediated phosphorylation at Ser-185/Ser-568/Thr-210, SUMOylation at Lys-238, ubiquitination) that regulate its subcellular partitioning to PML nuclear bodies, protein stability, and differential recruitment of coactivators (PCAF, p300) versus corepressors (RIP140, HDAC3, HDAC4, NuRD, DNMT1, LSD1/CoREST, TIF1β, TRIM28), thereby controlling globin gene switching in erythropoiesis, stem cell pluripotency (Oct4/Nanog), retinal development, and alternative telomere lengthening."},"narrative":{"teleology":[{"year":1989,"claim":"The molecular identity of TR2 as an orphan nuclear receptor was established, revealing a steroid receptor superfamily member with no known ligand, thereby opening the question of what biological functions it serves.","evidence":"cDNA cloning from human testis libraries with sequence analysis and in vitro translation","pmids":["2597158"],"confidence":"High","gaps":["No endogenous ligand identified","No target genes or biological function known","Expression pattern beyond testis not characterized"]},{"year":1997,"claim":"The DNA-binding specificity and dual transcriptional activity of TR2 were defined: it binds AGGTCA direct repeats (DR1–DR5) as homodimers via its ligand-binding domain, functioning as either a repressor (competing with RAR/RXR at DR5) or an activator (at DR4 sites), with the full-length LBD required for DNA binding and opposing activities of truncated isoforms.","evidence":"EMSA with Kd measurements, CAT/luciferase reporter assays, isoform comparison, domain mutagenesis across multiple target elements (CRBPII, RARβ, CRABP-I, aldolase A)","pmids":["8530418","9369481","9071982","7890658"],"confidence":"High","gaps":["Endogenous target genes in vivo not yet identified","Mechanism of context-dependent activation vs. repression unclear","In vivo relevance of homodimer binding not established"]},{"year":1998,"claim":"The corepressor and dimerization architecture of TR2 was resolved: RIP140 was identified as the first corepressor binding TR2 via LXXLL motifs at the AF-2 domain; TR2/TR4 heterodimers were shown to form preferentially and repress more strongly than homodimers; and a transferable silencing domain (DEF segment) with critical leucine residues on the dimer interface was mapped.","evidence":"Yeast two-hybrid, co-IP, GFP localization, pull-down assays, mammalian two-hybrid, EMSA, domain mutagenesis, reporter assays","pmids":["9774688","9737983","9660764"],"confidence":"High","gaps":["How TR2 chooses between repression and activation at different promoters unknown","No chromatin-level evidence for corepressor action","Physiological significance of TR2/TR4 heterodimer not established in vivo"]},{"year":1998,"claim":"The nuclear localization mechanism of TR2 was mapped to a 20-amino-acid constitutive NLS within the second zinc finger of the DNA-binding domain, and upstream regulation by p53 (repression upon ionizing radiation) and CNTF signaling was established.","evidence":"GFP fusion imaging with deletion mapping; radiation treatment with Northern blot and p53 epistasis; RT-PCR and reporter assays for CNTF pathway","pmids":["9795341","8663350","9694834"],"confidence":"High","gaps":["Physiological consequence of p53-mediated TR2 repression unclear","CNTF pathway connection not validated in vivo"]},{"year":2001,"claim":"TR2-mediated repression was linked to histone deacetylation: HDAC3 (class I) and HDAC4 (class II) directly interact with TR2 through its DNA-binding domain, and HDAC inhibitor TSA relieves TR2 repression, establishing an epigenetic mechanism for TR2 silencing activity.","evidence":"Co-IP, GST pull-down, far Western, deacetylase activity assay, reporter assays with TSA","pmids":["11463856","14521922"],"confidence":"High","gaps":["Which endogenous target genes are repressed via HDAC recruitment unknown","Relative contribution of HDAC3 vs. HDAC4 not resolved","No in vivo chromatin-level evidence at this stage"]},{"year":2002,"claim":"The physiological target of TR2/TR4 was identified: the DRED complex (~540 kDa TR2/TR4 heterodimer) binds DR1 sites in embryonic ε-globin and fetal γ-globin promoters, and an HPFH mutation disrupts this binding, directly implicating TR2/TR4 in developmental globin gene silencing. Separately, TR2 was shown to suppress estrogen receptor signaling through direct heterodimerization.","evidence":"Biochemical purification with mass spectrometry, EMSA with HPFH mutant DR1, transgenic mouse overexpression; GST pull-down and two-hybrid for ER interaction","pmids":["12093744","12093804"],"confidence":"High","gaps":["How TR2/TR4 distinguish embryonic from adult globin promoters not explained","Corepressor complexes on globin promoters not yet identified","ER interaction not validated in primary tissues"]},{"year":2006,"claim":"Post-translational modifications were shown to act as a molecular switch controlling TR2 output: PKC phosphorylation at Ser-185 (DBD) enhances DNA binding and PCAF coactivator recruitment, while SUMOylation at Lys-238 triggers release from PML nuclear bodies and coactivator-to-corepressor (PCAF→RIP140) exchange, converting TR2 from an Oct4 activator to a repressor.","evidence":"LC-ESI-MS/MS phosphosite identification, site-directed mutagenesis, EMSA, co-IP, GFP live imaging at PML bodies, ChIP, SUMOylation assays","pmids":["16317770","16130175","17187077"],"confidence":"High","gaps":["How SUMOylation physically displaces TR2 from PML bodies not resolved","Whether the PKC and SUMO modifications are coordinated or independent unclear","In vivo relevance for stem cell differentiation not yet demonstrated genetically"]},{"year":2008,"claim":"A complete atRA-triggered signaling cascade was delineated: atRA activates MEK/ERK2, which phosphorylates TR2 at Thr-210; phospho-TR2 is chaperoned to PML bodies by HDAC3 (independent of its deacetylase activity), undergoes SUMOylation, and switches from Oct4 activator to repressor, providing an integrated mechanism for retinoic acid-induced loss of pluripotency.","evidence":"Phosphorylation assays with Thr-210 mutagenesis, MEK/ERK inhibitors, co-IP, confocal microscopy, deacetylase-dead HDAC3 mutant rescue","pmids":["18682553","19204783"],"confidence":"High","gaps":["Whether this cascade operates in embryonic stem cells in vivo not shown","Structural basis for HDAC3 chaperone function unknown","Fate of TR2 after PML body targeting (degradation vs. stable repression) unclear"]},{"year":2011,"claim":"The full corepressor landscape at globin promoters was defined: TR2/TR4 recruit DNMT1, NuRD, LSD1/CoREST, HDAC3, and TIF1β specifically to embryonic β-globin promoters in adult erythroid cells; during terminal differentiation these corepressors remain at silenced embryonic promoters but dissociate from adult promoters, explaining developmental stage-specific silencing.","evidence":"Biotin-tagged purification with mass spectrometry, co-IP, ChIP comparing differentiated vs. undifferentiated erythroid cells","pmids":["21670149"],"confidence":"High","gaps":["How promoter-specific retention of corepressors is achieved unknown","Which corepressor is rate-limiting for silencing not determined","No evidence for direct DNA methylation by DNMT1 at these loci shown"]},{"year":2015,"claim":"Genetic proof that TR2/TR4 are required for embryonic globin silencing in adult erythropoiesis was obtained: compound conditional knockout of Tr2 and Tr4 in adult bone marrow reactivated embryonic εy and βh1 globins, abolished TR2/TR4 and corepressor occupancy at those promoters, and impaired terminal erythroid maturation.","evidence":"Conditional double knockout mouse, ChIP, RT-PCR, flow cytometry, in vitro bone marrow differentiation","pmids":["25561507"],"confidence":"High","gaps":["Whether TR2/TR4 loss can reactivate human fetal γ-globin therapeutically not tested","Mechanism of erythroid maturation defect beyond globin regulation not explored","Redundancy between TR2 and TR4 at individual promoters not fully parsed"]},{"year":2017,"claim":"A non-redundant role for NR2C1 in retinal development was established: Nr2c1 knockout mice exhibit severe vision deficits with disrupted early retinal progenitor patterning, including altered amacrine cell displacement and cone photoreceptor topography, with ChIP showing TR2 directly regulates early retinal transcription factors including Satb2.","evidence":"Nr2c1 knockout mouse, electroretinography, histology, immunofluorescence, ChIP","pmids":["28551284"],"confidence":"High","gaps":["Whether TR2 functions as activator or repressor of retinal target genes not fully resolved","Retinal phenotype relationship to TR2/TR4 heterodimer function not tested","Human retinal disease association not established"]},{"year":2025,"claim":"TR2 was implicated in alternative lengthening of telomeres (ALT) through recruitment of TRIM28/TIF1β to telomeric chromatin, promoting H3K9me3 heterochromatin formation; a TRIM28 variant unable to interact with orphan nuclear receptors failed to localize to telomeres or promote ALT phenotypes.","evidence":"Co-IP, ChIP, C-circle and APB assays, TRIM28 interaction-defective mutant in ALT cancer cell lines (preprint)","pmids":["bio_10.1101_2025.06.16.658187"],"confidence":"Medium","gaps":["Preprint not yet peer-reviewed","Relative contribution of TR2 vs. other orphan NRs (COUP-TFs, TR4) at telomeres not parsed","Whether TR2 is required for ALT in vivo not tested"]},{"year":null,"claim":"Key unresolved questions include: whether TR2 has an endogenous ligand, the structural basis for context-dependent switching between activation and repression, whether TR2/TR4-targeted therapies can reactivate fetal hemoglobin for sickle cell disease treatment, and how TR2's roles in retinal development, pluripotency, and telomere biology are integrated at the organismal level.","evidence":"","pmids":[],"confidence":"Low","gaps":["No endogenous ligand identified despite >35 years of study","No crystal structure of full-length TR2 or TR2/TR4 heterodimer available","Therapeutic targeting of TR2/TR4 for hemoglobin disorders not validated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[1,2,3,4,7,14,17,24]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,5,8,14,22,24,25,28]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[16,19]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[10,22,26,27]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[22,26,27]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[15,18,28]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,5,8,14,24,25,28]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[25,30]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[20,21,22,26]}],"complexes":["DRED (TR2/TR4 heterodimer)","NuRD","LSD1/CoREST"],"partners":["NR2C2","RIP140","HDAC3","HDAC4","PCAF","TRIM28","DNMT1","PML"],"other_free_text":[]},"mechanistic_narrative":"NR2C1 (TR2) is an orphan nuclear receptor that functions as a ligand-independent transcriptional regulator of globin gene switching, stem cell pluripotency, retinal development, and other developmental programs. TR2 binds AGGTCA direct repeat elements (DR1–DR5) as homodimers or as TR2/TR4 heterodimers, recruiting epigenetic corepressor complexes (DNMT1, NuRD, LSD1/CoREST, HDAC3, HDAC4, RIP140, TIF1β) to silence embryonic and fetal β-type globin genes in definitive erythroid cells, while conditional loss of both TR2 and TR4 reactivates embryonic globin expression and impairs terminal erythroid maturation [PMID:12093744, PMID:25561507, PMID:21670149]. Post-translational modifications act as a molecular switch controlling TR2 output: PKC-mediated phosphorylation at Ser-185 promotes DNA binding and PCAF coactivator recruitment for target gene activation, whereas ERK2-mediated phosphorylation at Thr-210 drives TR2 into PML nuclear bodies where SUMOylation at Lys-238 triggers coactivator-to-corepressor exchange (PCAF→RIP140), converting TR2 from an activator to a repressor of Oct4 [PMID:16317770, PMID:18682553, PMID:17187077]. Nr2c1 loss-of-function in mice causes severe visual deficits with disrupted early retinal cell patterning, establishing a non-redundant role in retinal development [PMID:28551284]."},"prefetch_data":{"uniprot":{"accession":"P13056","full_name":"Nuclear receptor subfamily 2 group C member 1","aliases":["Orphan nuclear receptor TR2","Testicular receptor 2"],"length_aa":603,"mass_kda":67.3,"function":"Orphan nuclear receptor. Binds the IR7 element in the promoter of its own gene in an autoregulatory negative feedback mechanism. Primarily repressor of a broad range of genes. Binds to hormone response elements (HREs) consisting of two 5'-AGGTCA-3' half site direct repeat consensus sequences. Together with NR2C2, forms the core of the DRED (direct repeat erythroid-definitive) complex that represses embryonic and fetal globin transcription. Also activator of OCT4 gene expression. May be involved in stem cell proliferation and differentiation. Mediator of retinoic acid-regulated preadipocyte proliferation","subcellular_location":"Nucleus; Nucleus, PML body","url":"https://www.uniprot.org/uniprotkb/P13056/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NR2C1","classification":"Not Classified","n_dependent_lines":7,"n_total_lines":1208,"dependency_fraction":0.005794701986754967},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NR2C1","total_profiled":1310},"omim":[{"mim_id":"617962","title":"ZINC FINGER PROTEIN 827; ZNF827","url":"https://www.omim.org/entry/617962"},{"mim_id":"602490","title":"NUCLEAR RECEPTOR-INTERACTING PROTEIN 1; NRIP1","url":"https://www.omim.org/entry/602490"},{"mim_id":"601529","title":"NUCLEAR RECEPTOR SUBFAMILY 2, GROUP C, MEMBER 1; NR2C1","url":"https://www.omim.org/entry/601529"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cell Junctions","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/NR2C1"},"hgnc":{"alias_symbol":["TR2-11"],"prev_symbol":["TR2"]},"alphafold":{"accession":"P13056","domains":[{"cath_id":"3.30.50.10","chopping":"121-181","consensus_level":"high","plddt":95.6884,"start":121,"end":181},{"cath_id":"1.10.565.10","chopping":"370-595","consensus_level":"high","plddt":87.897,"start":370,"end":595}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P13056","model_url":"https://alphafold.ebi.ac.uk/files/AF-P13056-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P13056-F1-predicted_aligned_error_v6.png","plddt_mean":64.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NR2C1","jax_strain_url":"https://www.jax.org/strain/search?query=NR2C1"},"sequence":{"accession":"P13056","fasta_url":"https://rest.uniprot.org/uniprotkb/P13056.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P13056/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P13056"}},"corpus_meta":[{"pmid":"9739048","id":"PMC_9739048","title":"LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer.","date":"1998","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9739048","citation_count":211,"is_preprint":false},{"pmid":"9765287","id":"PMC_9765287","title":"Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9765287","citation_count":192,"is_preprint":false},{"pmid":"16319225","id":"PMC_16319225","title":"Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16319225","citation_count":189,"is_preprint":false},{"pmid":"9774688","id":"PMC_9774688","title":"Cloning and characterization of mouse RIP140, a corepressor for nuclear orphan receptor TR2.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9774688","citation_count":113,"is_preprint":false},{"pmid":"21670149","id":"PMC_21670149","title":"Nuclear receptors TR2 and TR4 recruit multiple epigenetic transcriptional corepressors that associate specifically with the embryonic β-type globin promoters in differentiated adult erythroid cells.","date":"2011","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21670149","citation_count":106,"is_preprint":false},{"pmid":"12093744","id":"PMC_12093744","title":"An embryonic/fetal beta-type globin gene repressor contains a nuclear receptor TR2/TR4 heterodimer.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12093744","citation_count":98,"is_preprint":false},{"pmid":"9712045","id":"PMC_9712045","title":"Antibodies to TR2 (herpesvirus entry mediator), a new member of the TNF receptor superfamily, block T cell proliferation, expression of activation markers, and production of cytokines.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9712045","citation_count":96,"is_preprint":false},{"pmid":"2597158","id":"PMC_2597158","title":"Molecular cloning of new human TR2 receptors: a class of steroid receptor with multiple ligand-binding domains.","date":"1989","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/2597158","citation_count":94,"is_preprint":false},{"pmid":"12615731","id":"PMC_12615731","title":"Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12615731","citation_count":87,"is_preprint":false},{"pmid":"17431400","id":"PMC_17431400","title":"Embryonic and fetal beta-globin gene repression by the orphan nuclear receptors, TR2 and TR4.","date":"2007","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/17431400","citation_count":86,"is_preprint":false},{"pmid":"12361719","id":"PMC_12361719","title":"Recent advances in the TR2 and TR4 orphan receptors of the nuclear receptor superfamily.","date":"2002","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12361719","citation_count":79,"is_preprint":false},{"pmid":"18682553","id":"PMC_18682553","title":"Retinoic acid-stimulated sequential phosphorylation, PML recruitment, and SUMOylation of nuclear receptor TR2 to suppress Oct4 expression.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18682553","citation_count":65,"is_preprint":false},{"pmid":"8530418","id":"PMC_8530418","title":"Multiple functions of the TR2-11 orphan receptor in modulating activation of two key cis-acting elements involved in the retinoic acid signal transduction system.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8530418","citation_count":57,"is_preprint":false},{"pmid":"34234757","id":"PMC_34234757","title":"Isolation and Characterization of a Novel Salmonella Phage vB_SalP_TR2.","date":"2021","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/34234757","citation_count":55,"is_preprint":false},{"pmid":"7890658","id":"PMC_7890658","title":"Identification of human TR2 orphan receptor response element in the transcriptional initiation site of the simian virus 40 major late promoter.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7890658","citation_count":54,"is_preprint":false},{"pmid":"17187077","id":"PMC_17187077","title":"SUMOylation of Tr2 orphan receptor involves Pml and fine-tunes Oct4 expression in stem cells.","date":"2006","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17187077","citation_count":46,"is_preprint":false},{"pmid":"17974920","id":"PMC_17974920","title":"The TR2 and TR4 orphan nuclear receptors repress Gata1 transcription.","date":"2007","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/17974920","citation_count":45,"is_preprint":false},{"pmid":"8663350","id":"PMC_8663350","title":"p53 is a mediator for radiation-repressed human TR2 orphan receptor expression in MCF-7 cells, a new pathway from tumor suppressor to member of the steroid receptor superfamily.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8663350","citation_count":43,"is_preprint":false},{"pmid":"22042865","id":"PMC_22042865","title":"Forced TR2/TR4 expression in sickle cell disease mice confers enhanced fetal hemoglobin synthesis and alleviated disease phenotypes.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22042865","citation_count":42,"is_preprint":false},{"pmid":"9737983","id":"PMC_9737983","title":"A novel nuclear receptor heterodimerization pathway mediated by orphan receptors TR2 and TR4.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9737983","citation_count":39,"is_preprint":false},{"pmid":"12093804","id":"PMC_12093804","title":"Suppression of estrogen receptor-mediated transcription and cell growth by interaction with TR2 orphan receptor.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12093804","citation_count":38,"is_preprint":false},{"pmid":"28527578","id":"PMC_28527578","title":"TR2 and TR4 Orphan Nuclear Receptors: An Overview.","date":"2017","source":"Current topics in developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/28527578","citation_count":35,"is_preprint":false},{"pmid":"9694834","id":"PMC_9694834","title":"A bidirectional regulation between the TR2/TR4 orphan receptors (TR2/TR4) and the ciliary neurotrophic factor (CNTF) signaling pathway.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9694834","citation_count":29,"is_preprint":false},{"pmid":"11463856","id":"PMC_11463856","title":"The orphan nuclear receptor TR2 interacts directly with both class I and class II histone deacetylases.","date":"2001","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/11463856","citation_count":27,"is_preprint":false},{"pmid":"17389641","id":"PMC_17389641","title":"Orphan nuclear receptor TR2, a mediator of preadipocyte proliferation, is differentially regulated by RA through exchange of coactivator PCAF with corepressor RIP140 on a platform molecule GRIP1.","date":"2007","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/17389641","citation_count":25,"is_preprint":false},{"pmid":"3023604","id":"PMC_3023604","title":"Initiation of swimming activity by trigger neurons in the leech subesophageal ganglion. III. Sensory inputs to Tr1 and Tr2.","date":"1986","source":"Journal of comparative physiology. A, Sensory, neural, and behavioral physiology","url":"https://pubmed.ncbi.nlm.nih.gov/3023604","citation_count":25,"is_preprint":false},{"pmid":"12949936","id":"PMC_12949936","title":"TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3.","date":"2003","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/12949936","citation_count":24,"is_preprint":false},{"pmid":"9071982","id":"PMC_9071982","title":"Distinct expression patterns and biological activities of two isoforms of the mouse orphan receptor TR2.","date":"1997","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9071982","citation_count":24,"is_preprint":false},{"pmid":"9660764","id":"PMC_9660764","title":"Mechanisms of the mouse orphan nuclear receptor TR2-11-mediated gene suppression.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9660764","citation_count":23,"is_preprint":false},{"pmid":"9369481","id":"PMC_9369481","title":"The orphan nuclear receptor TR2 suppresses a DR4 hormone response element of the mouse CRABP-I gene promoter.","date":"1997","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9369481","citation_count":22,"is_preprint":false},{"pmid":"25561507","id":"PMC_25561507","title":"Compound loss of function of nuclear receptors Tr2 and Tr4 leads to induction of murine embryonic β-type globin genes.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25561507","citation_count":22,"is_preprint":false},{"pmid":"10393558","id":"PMC_10393558","title":"Characterization of an inverted repeat with a zero spacer (IR0)-type retinoic acid response element from the mouse nuclear orphan receptor TR2-11 gene.","date":"1999","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10393558","citation_count":22,"is_preprint":false},{"pmid":"36591938","id":"PMC_36591938","title":"NamiRNA-enhancer network of miR-492 activates the NR2C1-TGF-β/Smad3 pathway to promote epithelial-mesenchymal transition of pancreatic cancer.","date":"2023","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/36591938","citation_count":21,"is_preprint":false},{"pmid":"27075724","id":"PMC_27075724","title":"Functional Divergence of the Nuclear Receptor NR2C1 as a Modulator of Pluripotentiality During Hominid Evolution.","date":"2016","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27075724","citation_count":21,"is_preprint":false},{"pmid":"9795341","id":"PMC_9795341","title":"A constitutive nuclear localization signal from the second zinc-finger of orphan nuclear receptor TR2.","date":"1998","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9795341","citation_count":20,"is_preprint":false},{"pmid":"10766818","id":"PMC_10766818","title":"Constitutive activation of retinoic acid receptor beta2 promoter by orphan nuclear receptor TR2.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10766818","citation_count":19,"is_preprint":false},{"pmid":"9879671","id":"PMC_9879671","title":"Thyroid hormone direct repeat 4 response element is a positive regulatory element for the human TR2 orphan receptor, a member of steroid receptor superfamily.","date":"1998","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9879671","citation_count":18,"is_preprint":false},{"pmid":"16317770","id":"PMC_16317770","title":"Ligand-independent orphan receptor TR2 activation by phosphorylation at the DNA-binding domain.","date":"2006","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/16317770","citation_count":15,"is_preprint":false},{"pmid":"19204783","id":"PMC_19204783","title":"HDAC3 as a molecular chaperone for shuttling phosphorylated TR2 to PML: a novel deacetylase activity-independent function of HDAC3.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19204783","citation_count":15,"is_preprint":false},{"pmid":"16130175","id":"PMC_16130175","title":"Protein kinase C-mediated phosphorylation of orphan nuclear receptor TR2: effects on receptor stability and activity.","date":"2005","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/16130175","citation_count":15,"is_preprint":false},{"pmid":"16839558","id":"PMC_16839558","title":"SmTR2/4, a Schistosoma mansoni homologue of TR2/TR4 orphan nuclear receptor.","date":"2006","source":"International journal for parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/16839558","citation_count":14,"is_preprint":false},{"pmid":"10391141","id":"PMC_10391141","title":"Identification of the histamine H1 receptor gene as a differentially repressed target of the human TR2 orphan receptor.","date":"1999","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10391141","citation_count":14,"is_preprint":false},{"pmid":"9704569","id":"PMC_9704569","title":"The genomic structure and chromosomal location of the human TR2 orphan receptor, a member of the steroid receptor superfamily.","date":"1998","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/9704569","citation_count":12,"is_preprint":false},{"pmid":"17010934","id":"PMC_17010934","title":"Transcriptional regulation of the human TR2 orphan receptor gene by nuclear factor 1-A.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17010934","citation_count":11,"is_preprint":false},{"pmid":"7841789","id":"PMC_7841789","title":"Molecular cloning of a novel member of the nuclear receptor superfamily related to the orphan receptor, TR2.","date":"1994","source":"Gene expression","url":"https://pubmed.ncbi.nlm.nih.gov/7841789","citation_count":10,"is_preprint":false},{"pmid":"9196064","id":"PMC_9196064","title":"Identification of the human aldolase A gene as the first induced target for the TR2 orphan receptor, a member of the steroid hormone receptor superfamily.","date":"1997","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9196064","citation_count":10,"is_preprint":false},{"pmid":"9535784","id":"PMC_9535784","title":"Striking evolutionary conservation of a cis-element related to nuclear receptor target sites and present in TR2 orphan receptor genes.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9535784","citation_count":10,"is_preprint":false},{"pmid":"28551284","id":"PMC_28551284","title":"The nuclear hormone receptor gene Nr2c1 (Tr2) is a critical regulator of early retina cell patterning.","date":"2017","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/28551284","citation_count":9,"is_preprint":false},{"pmid":"2836627","id":"PMC_2836627","title":"Cell-mediated immunity induced in mice after vaccination with a protease activation mutant, TR-2, of Sendai virus.","date":"1988","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/2836627","citation_count":9,"is_preprint":false},{"pmid":"10807954","id":"PMC_10807954","title":"Characterization of the mouse nuclear orphan receptor TR2-11 gene promoter and its potential role in retinoic acid-induced P19 apoptosis.","date":"2000","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10807954","citation_count":9,"is_preprint":false},{"pmid":"39215190","id":"PMC_39215190","title":"Molecular classification of ovarian high-grade serous/endometrioid carcinomas through multi-omics analysis: JGOG3025-TR2 study.","date":"2024","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39215190","citation_count":8,"is_preprint":false},{"pmid":"16452526","id":"PMC_16452526","title":"Expression of orphan receptors TR2, TR3, TR4, and p53 in heat-treated testis of cynomolgus monkeys (Macaca fascicularis).","date":"2006","source":"Journal of andrology","url":"https://pubmed.ncbi.nlm.nih.gov/16452526","citation_count":8,"is_preprint":false},{"pmid":"17645519","id":"PMC_17645519","title":"Collective repression of the hepatitis B virus enhancer II by human TR4 and TR2 orphan receptors.","date":"2007","source":"Hepatology research : the official journal of the Japan Society of Hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/17645519","citation_count":8,"is_preprint":false},{"pmid":"38790192","id":"PMC_38790192","title":"Roles of Nuclear Orphan Receptors TR2 and TR4 during Hematopoiesis.","date":"2024","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/38790192","citation_count":7,"is_preprint":false},{"pmid":"11358973","id":"PMC_11358973","title":"Feedback regulation between orphan nuclear receptor TR2 and human papilloma virus type 16.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11358973","citation_count":7,"is_preprint":false},{"pmid":"9503600","id":"PMC_9503600","title":"Molecular cloning from neurulating Ambystoma mexicanum embryos of the cDNA encoding an orphan nuclear receptor (aDOR1) closely related to TR2-11.","date":"1997","source":"Differentiation; research in biological diversity","url":"https://pubmed.ncbi.nlm.nih.gov/9503600","citation_count":7,"is_preprint":false},{"pmid":"14521922","id":"PMC_14521922","title":"Identification of histone deacetylase-3 domains that interact with the orphan nuclear receptor TR2.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/14521922","citation_count":7,"is_preprint":false},{"pmid":"29272788","id":"PMC_29272788","title":"Combination of novel DR5 targeting agonistic scFv antibody TR2-3 with cisplatin shows enhanced synergistic antitumor activity in vitro and in vivo.","date":"2017","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/29272788","citation_count":7,"is_preprint":false},{"pmid":"26712358","id":"PMC_26712358","title":"Testicular receptor 2, Nr2c1, is associated with stem cells in the developing olfactory epithelium and other cranial sensory and skeletal structures.","date":"2015","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/26712358","citation_count":7,"is_preprint":false},{"pmid":"10855696","id":"PMC_10855696","title":"Identification of an essential cis-acting element (TR2-PACE) in the 5' promoter of human TR2 orphan receptor gene.","date":"2000","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/10855696","citation_count":7,"is_preprint":false},{"pmid":"10520740","id":"PMC_10520740","title":"Cloning of a cDNA for xDOR2, a novel TR2-related nuclear orphan receptor, expressed during neurulation in Xenopus laevis embryos.","date":"1998","source":"DNA sequence : the journal of DNA sequencing and mapping","url":"https://pubmed.ncbi.nlm.nih.gov/10520740","citation_count":3,"is_preprint":false},{"pmid":"12615366","id":"PMC_12615366","title":"Differential and bi-directional regulation between TR2/TR4 orphan nuclear receptors and a specific ligand mediated-peroxisome proliferator-activated receptor alpha in human HaCaT keratinocytes.","date":"2003","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/12615366","citation_count":3,"is_preprint":false},{"pmid":"9504722","id":"PMC_9504722","title":"Polymorphism in the murine Tr2-11 gene encoding an orphan receptor, and its exclusion as a candidate gene for the cataract mutation Cat3.","date":"1998","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9504722","citation_count":3,"is_preprint":false},{"pmid":"40563438","id":"PMC_40563438","title":"Orphan Nuclear Receptors TR2 and TR4 in Erythropoiesis: From Mechanisms to Therapies.","date":"2025","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/40563438","citation_count":1,"is_preprint":false},{"pmid":"26238624","id":"PMC_26238624","title":"Post-translational modifications of orphan nuclear receptor TR2 - new insights into drug targets for stem cell therapy and the effect of retinoic acid.","date":"2009","source":"Proteomics. Clinical applications","url":"https://pubmed.ncbi.nlm.nih.gov/26238624","citation_count":1,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.02.19.639178","title":"Design, development, and evaluation of gene therapeutics specific to KSHV-associated diseases","date":"2025-02-19","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.19.639178","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.16.658187","title":"Orphan nuclear receptors recruit TRIM28 to promote telomeric H3K9me3 for the alternative lengthening of telomeres pathway","date":"2025-06-19","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.16.658187","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":30956,"output_tokens":8004,"usd":0.106464},"stage2":{"model":"claude-opus-4-6","input_tokens":11939,"output_tokens":3921,"usd":0.23658},"total_usd":0.343044,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1989,\n      \"finding\": \"NR2C1 (TR2) was molecularly cloned from human testis cDNA libraries as a new member of the steroid receptor superfamily containing conserved zinc-finger DNA-binding domains; multiple isoforms with distinct ligand-binding domain lengths were identified, and no binding activity with known steroid hormones was found, classifying it as an orphan receptor.\",\n      \"method\": \"cDNA cloning, in vitro translation, sequence analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning paper with in vitro translation and sequence characterization\",\n      \"pmids\": [\"2597158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"TR2 orphan receptor binds hormone response elements containing AGGTCA direct repeat sequences with preference order DR1 > DR2 > DR5 ≥ DR4 > DR6 > DR3, and competes with RXRα and RARα/RXRα heterodimers at CRBPIIp (DR1) and RARβ (DR5) response elements to suppress retinoic acid-stimulated transcription without forming heterodimers with RXRα or RARα.\",\n      \"method\": \"CAT reporter assays, gel mobility shift assays (EMSA), competition binding\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro DNA binding with Kd measurements plus functional reporter assays\",\n      \"pmids\": [\"8530418\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"A natural TR2 response element (TR2RE-SV40) was identified in the SV40 +55 region with high affinity binding (Kd = 9 nM); TR2 binding to this element represses both SV40 early and late promoter transcriptional activities.\",\n      \"method\": \"EMSA with in vitro translated TR2, CAT reporter assays, DNA-swap experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro binding with Kd measurement plus functional reporter assays with mutagenesis\",\n      \"pmids\": [\"7890658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The TR2 orphan receptor (TR2-11-f) binds as homodimers to a DR4 hormone response element in the mouse CRABP-I gene promoter (Kd = 2.6 nM) through its ligand-binding domain, and suppresses CRABP-I reporter gene expression.\",\n      \"method\": \"Gel retardation assay, yeast two-hybrid, CAT reporter assays\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro binding with Kd, dimerization domain mapping, functional reporter assays\",\n      \"pmids\": [\"9369481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TR2 binds the M1 site in the human aldolase A muscle-specific promoter (Kd = 4.6 nM), induces localized DNA bending (~73°), and functions as a transcriptional inducer of aldolase A expression in muscle cells.\",\n      \"method\": \"EMSA, circular permutation assay, dual-luciferase reporter assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro binding with Kd and bend angle; single lab\",\n      \"pmids\": [\"9196064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Two TR2 isoforms (TR2-11 and truncated TR2-11-t lacking the ligand-binding domain) have opposing biological activities: TR2-11 represses RA induction via a DR5-type RARE and binds DNA as dimers, whereas TR2-11-t enhances RA induction and cannot bind DNA; the full-length LBD is required for DNA binding and repression.\",\n      \"method\": \"CAT reporter assays, gel-shift assays, prokaryotic expression, isoform characterization\",\n      \"journal\": \"The Journal of endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct functional comparison of isoforms with DNA binding and reporter assays\",\n      \"pmids\": [\"9071982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Mouse RIP140 was identified as a corepressor for TR2; RIP140 interacts with TR2 through LXXLL motifs binding to the C-terminal AF-2 region of TR2's LBD; in the presence of RIP140, cytosolic GFP-tagged TR2 LBD translocates to the nucleus; RIP140 represses TR2-mediated and RA receptor-mediated transcription in reporter assays.\",\n      \"method\": \"Yeast two-hybrid, coimmunoprecipitation, GFP localization, GAL4 reporter assays, domain mapping\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — yeast two-hybrid + in vivo coIP + GFP localization + functional reporter, multiple orthogonal methods\",\n      \"pmids\": [\"9774688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"TR2 and TR4 preferentially form heterodimers in solution and on DR5 DNA elements; heterodimerization is mediated by the ligand-binding domains, with three leucine residues on helix 10 of TR2 critical for interaction; TR2/TR4 coexpression exerts stronger repression on a DR5 reporter than either receptor alone.\",\n      \"method\": \"Yeast two-hybrid, mammalian two-hybrid, pull-down assay, EMSA, GFP colocalization, reporter assays, domain mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including pulldown, two-hybrid, EMSA, live-cell imaging, and mutagenesis\",\n      \"pmids\": [\"9737983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"TR2 repressor activity requires high-affinity DNA binding, receptor dimerization, and an active silencing domain (DEF segment); a transferable trans-repressive activity resides in the DEF segment including C-terminal 49 amino acids; point mutations at three conserved leucines on the predicted dimer interface abolish suppressive activity, dimerization, and DNA binding.\",\n      \"method\": \"GAL4 reporter assays, deletion and point mutagenesis, functional domain mapping\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis with multiple functional readouts\",\n      \"pmids\": [\"9660764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"TR2 bidirectionally interacts with the CNTF signaling pathway: CNTF induces TR2 expression, and TR2 in turn activates CNTFRα transcription through a direct repeat response element (AGGTCA) in the CNTFRα intron 5; TR2 and CNTFRα show overlapping expression in developing neural structures.\",\n      \"method\": \"Reporter assays (CAT), RT-PCR, in situ hybridization, DNA binding assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional reporter + expression studies; single lab\",\n      \"pmids\": [\"9694834\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"TR2 is exclusively localized to the nucleus via a constitutive nuclear localization signal comprising 20 amino acids (KDCVINKHHRNRCQYCRLQR) within the second zinc-finger of the DNA-binding domain; no NLS activity was found in the N-terminus or LBD; nuclear-localized GFP-TR2 retains repressive activity on DR5 reporters.\",\n      \"method\": \"GFP fusion live-cell imaging, HA-antibody detection, deletion analysis, EMSA\",\n      \"journal\": \"The Journal of endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — live-cell GFP imaging + deletion mapping + functional validation\",\n      \"pmids\": [\"9795341\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"TR2 shows transactivation via a DR4-TRE element and competes with unliganded TRα1/RXRα heterodimer; TR2 cancels the suppressive effect of unliganded TRα1 on CAT reporter activity in a dose-dependent, DNA-binding–dependent manner.\",\n      \"method\": \"EMSA, CAT reporter assays, competition binding\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — binding and functional assays; single lab, single study\",\n      \"pmids\": [\"9879671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Ionizing radiation represses TR2 expression at both transcriptional and translational levels; p53 (endogenously induced or exogenously transfected) represses TR2 gene expression, and this repression is reversed by SV40 large T antigen co-transfection, placing p53 upstream of TR2 in the radiation response.\",\n      \"method\": \"Transient transfection, CAT reporter assays, Northern blot, radiation treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis by gain/loss of p53 plus reporter assays; single lab\",\n      \"pmids\": [\"8663350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"An IR0-type retinoic acid response element in the TR2-11 gene proximal promoter is bound specifically by RARα/RXRβ heterodimers (Kd ~8 nM) but not by either receptor alone; this element mediates RA-induced transcription of the TR2-11 gene.\",\n      \"method\": \"EMSA, reporter assays, gel mobility shift with nuclear extracts\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro binding with Kd determination plus functional reporter; single lab\",\n      \"pmids\": [\"10393558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TR2 constitutively activates endogenous RARβ2 gene expression in P19 cells via the DR5 element in the RARβ2 promoter; cAMP enhances this activation via the CRE; the constitutive activation function (AF-1) maps to residues 10–30 in the N-terminal A segment; TR2 and CREMτ directly interact (co-IP) via the TR2 N-terminal AB segment.\",\n      \"method\": \"Reporter assays, EMSA competition, coimmunoprecipitation, domain mapping, Northern blot\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple methods: functional reporter + EMSA + co-IP + domain mapping\",\n      \"pmids\": [\"10766818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TR2 directly interacts with class I (HDAC3) and class II (HDAC4) histone deacetylases; the DNA-binding domain of TR2 mediates the interaction with both HDACs (not the LBD); TR2-HDAC complexes exhibit deacetylase activity in vitro; HDAC inhibitor trichostatin A relieves TR2-mediated transcriptional repression.\",\n      \"method\": \"Co-IP with FLAG-tagged HDACs, GST pull-down, far Western blot, deacetylase activity assay, reporter assays with TSA\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro pull-down + co-IP with endogenous proteins + deacetylase activity assay + functional rescue\",\n      \"pmids\": [\"11463856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"TR2 forms a heterodimer with the estrogen receptor (ER) that disrupts ER homodimerization and ER DNA binding, thereby suppressing ER-mediated transcription; an interaction-blocking peptide (ER-6, aa 312–340) reverses this suppression; antisense TR2 in MCF7 cells enhances ER transcriptional activity; TR2-mediated ER suppression inhibits estrogen-induced cell growth and G1/S transition.\",\n      \"method\": \"GST pull-down, mammalian two-hybrid, CAT reporter assays, antisense knockdown, cell proliferation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pulldown + two-hybrid + functional reporter + cell-based loss-of-function; multiple orthogonal methods\",\n      \"pmids\": [\"12093804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"TR2 and TR4 form a heterodimer (DRED complex, ~540 kDa) that binds DR1 sites in the human embryonic ε-globin and fetal γ-globin gene promoters with high affinity; an HPFH mutation in the DR1 site reduces TR2/TR4 binding in vitro; transgenic forced expression of TR2/TR4 reduces endogenous embryonic εy-globin transcription in mice.\",\n      \"method\": \"Biochemical purification, mass spectrometry, EMSA, EMSA competition with mutant DR1, transgenic mouse expression\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — complex purification + MS identification + EMSA with Kd + in vivo transgenic validation\",\n      \"pmids\": [\"12093744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"HDAC3 interacts with TR2 through two domains: N-terminal residues 1–135 (specifically 1–70) and C-terminal residues 210–428 (specifically 270–320); these two binding sites compete for TR2; the TR2-HDAC3 complex formed on TR2 DNA target sequences exhibits histone deacetylase activity in vivo.\",\n      \"method\": \"GST pull-down, coimmunoprecipitation, ChIP, histone deacetylase activity assay, domain mapping\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro pulldown domain mapping + co-IP + ChIP + deacetylase activity assay\",\n      \"pmids\": [\"14521922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TR2 suppresses androgen receptor (AR)-mediated transactivation and PSA expression in prostate cancer PC-3 cells through direct protein-protein interaction with AR (demonstrated by GST pulldown and mammalian two-hybrid), not by competing for common coregulators.\",\n      \"method\": \"CAT reporter assays, Northern blot, GST pull-down, mammalian two-hybrid\",\n      \"journal\": \"The Prostate\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pulldown + two-hybrid + functional assays; single lab\",\n      \"pmids\": [\"12949936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PKC phosphorylates TR2 at Ser-568 and Ser-461 in the LBD; Ser-568 phosphorylation is required for PKC-mediated enhancement of TR2 protein stability (protection from proteasome-mediated degradation) and transcriptional activation of its target gene RARβ.\",\n      \"method\": \"In vivo metabolic labeling, kinase/phosphatase inhibitor treatment, LC-ESI-MS/MS, site-directed mutagenesis, reporter assays, proteasome inhibitor experiments\",\n      \"journal\": \"Proteomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — MS-confirmed phosphosites + mutagenesis + functional activity assays\",\n      \"pmids\": [\"16130175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PKC phosphorylates TR2 at Ser-185 in the DNA-binding domain (confirmed by MS); DBD phosphorylation facilitates TR2 DNA binding and recruitment of coactivator PCAF; Ser-185 is required for DNA binding, and both Ser-170 and Ser-185 are necessary for PCAF interaction; double mutant significantly reduces RARβ2 activation.\",\n      \"method\": \"LC-ESI-MS/MS, site-directed mutagenesis, EMSA, co-IP, reporter assays\",\n      \"journal\": \"Proteomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — MS phosphosite identification + mutagenesis + EMSA + coIP + functional assays\",\n      \"pmids\": [\"16317770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TR2 can be SUMOylated at Lys-238; unSUMOylated TR2 localizes to PML nuclear bodies and activates Oct4 (recruiting coactivator PCAF), whereas elevated TR2 abundance triggers SUMOylation, release from PML bodies, and coregulator exchange: PCAF is replaced by corepressor RIP140, converting TR2 from an activator to a repressor of Oct4.\",\n      \"method\": \"SUMOylation assays, coimmunoprecipitation, GFP live imaging, ChIP, reporter assays, knockdown experiments\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods; Nature structural publication with mechanistic detail\",\n      \"pmids\": [\"17187077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TR2 is a preadipocyte proliferator that activates c-Myc via an IR0-type RA response element; in preadipocytes RA induces GRIP1/PCAF coactivator complex recruitment to the TR2 promoter (promoting TR2 expression), while in differentiated adipocytes RA induces GRIP1/RIP140 corepressor complex recruitment (repressing TR2); GRIP1 directly interacts with both PCAF and RIP140 and serves as a platform molecule.\",\n      \"method\": \"siRNA knockdown, reporter assays, ChIP, co-IP, domain mapping, 3T3-L1 cell model\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP + co-IP + knockdown + functional assays with multiple coregulators; multiple methods\",\n      \"pmids\": [\"17389641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TR2/TR4 directly represses GATA1/Gata1 transcription in murine and human erythroid progenitor cells through binding to an evolutionarily conserved DR element within the GATA1 hematopoietic enhancer (G1HE); TR2/TR4 binding was shown by EMSA and ChIP, and mutation of the DR element elevated Gata1 promoter activity and reduced TR2/TR4 responsiveness.\",\n      \"method\": \"EMSA, ChIP, reporter assays with DR site mutagenesis, transgenic mice, null mutant mice, shRNA knockdown in CD34+ cells\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — EMSA + ChIP + mutagenesis + in vivo gain/loss-of-function replicated in multiple systems\",\n      \"pmids\": [\"17974920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TR2/TR4 play critical roles in developmental silencing of embryonic β-type globin genes (εy and γ); TR2 and TR4 null mutant mice show delayed silencing of embryonic and fetal β-globin genes; dominant-negative TR4 activates human ε-globin in both primitive and definitive erythroid cells, but activates γ-globin only in definitive erythroid cells; forced expression of TR2/TR4 causes precocious ε-globin repression.\",\n      \"method\": \"Knockout mice, transgenic mice (dominant-negative and forced expression), RT-PCR, Southern blot, in situ hybridization\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic gain and loss of function in multiple mouse models, replicated in different genetic backgrounds\",\n      \"pmids\": [\"17431400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"All-trans retinoic acid (atRA) triggers a nongenomic signaling cascade: atRA → MEK/ERK2 complex formation → ERK2 phosphorylates TR2 at Thr-210 → phospho-TR2 associates increasingly with PML nuclear bodies and undergoes SUMOylation → corepressor RIP140 replaces coactivator PCAF → TR2 switches from activator to repressor of Oct4; unphosphorylated TR2 recruits PCAF and activates Oct4.\",\n      \"method\": \"Phosphorylation assays, site-directed mutagenesis (Thr-210), co-IP, ChIP, confocal microscopy, reporter assays, inhibitor studies (MEK/ERK inhibitors)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods with site-specific mutagenesis and pathway inhibitors\",\n      \"pmids\": [\"18682553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"HDAC3 acts as a molecular chaperone to shuttle phosphorylated TR2 (phospho-Thr-210) to PML nuclear bodies; this chaperone function is independent of HDAC3 deacetylase activity; atRA also stimulates nuclear enrichment of HDAC3 and its complex formation with PML in an ERK2-independent manner.\",\n      \"method\": \"Co-IP, in vitro binding assays, confocal microscopy, deacetylase-dead HDAC3 mutants, PML recruitment assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro and in vivo assays with deacetylase-inactive mutant to separate functions; multiple methods\",\n      \"pmids\": [\"19204783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TR2 and TR4 recruit multiple epigenetic corepressor complexes (DNMT1, NuRD, LSD1/CoREST, HDAC3, TIF1β) to embryonic β-type globin promoters in differentiated adult erythroid cells; ChIP shows TR2/TR4 bind embryonic but not adult β-globin promoters; upon terminal differentiation, corepressors dissociate selectively from the adult promoter but remain at silenced embryonic promoters.\",\n      \"method\": \"Biotin-tagged protein complex purification, mass spectrometry, co-IP, ChIP in differentiated vs. undifferentiated erythroid cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical purification + MS identification + co-IP + ChIP with developmental stage comparison; replicated with multiple corepressors\",\n      \"pmids\": [\"21670149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Compound conditional knockout of both Tr2 and Tr4 in adult bone marrow cells induces expression of embryonic εy and βh1 globins; loss of TR2/TR4 abolishes their occupancy on εy and βh1 promoters and impairs co-occupancy by interacting corepressors; TR2/TR4 function is also required for terminal erythroid cell maturation.\",\n      \"method\": \"Conditional knockout mouse genetics, in vitro bone marrow differentiation, ChIP, RT-PCR, flow cytometry\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional double KO with ChIP showing loss of promoter occupancy and corepressor co-occupancy\",\n      \"pmids\": [\"25561507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Nr2c1 (Tr2) loss-of-function in mice causes severe vision deficits, disrupts early retinal cell patterning (increased displaced amacrine cells, altered cone photoreceptor topography), and affects early but not late retinal cell types; ChIP experiments show NR2C1 regulates early retinal progenitor transcription factors including Satb2 (amacrine) and cone photoreceptor regulators (thyroid and retinoic acid receptors).\",\n      \"method\": \"Nr2c1 knockout mouse, electroretinography, histology, ChIP, immunofluorescence\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo KO with defined cellular phenotype + ChIP identifying direct target regulators\",\n      \"pmids\": [\"28551284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Evolutionary analysis and functional assays of human, chimpanzee, and ancestral NR2C1 proteins showed that hominid-specific changes in NR2C1 alter its ability to modulate Oct4 and Nanog transcription (pluripotency regulators), Pepck promoter activity (a differentiation proxy), and embryonic stem cell colony size, indicating NR2C1 underwent adaptive evolution affecting stem cell pluripotency regulation.\",\n      \"method\": \"Codon evolution analysis, reporter assays, stem cell colony assays, ancestral sequence reconstruction\",\n      \"journal\": \"Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional assays with reconstructed ancestral protein; single study\",\n      \"pmids\": [\"27075724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In pancreatic cancer, miR-492 acts as an enhancer trigger that activates NR2C1 expression; NR2C1 promotes epithelial-mesenchymal transition (EMT) through the TGF-β/Smad3 signaling pathway; CRISPR-Cas9 and ChIP assays confirmed miR-492 enhancer regulation of NR2C1, and antagomiR-492 suppressed tumorigenesis by downregulating NR2C1.\",\n      \"method\": \"CRISPR-Cas9, ChIP, in vitro migration/invasion assays, in vivo xenograft, Western blot, knockdown/overexpression\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR + ChIP + in vivo validation; single lab\",\n      \"pmids\": [\"36591938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TR2 (along with COUP-TF1, COUP-TF2, and TR4) promotes telomeric H3K9me3 and alternative lengthening of telomeres (ALT) by recruiting TRIM28 to telomeres; physical interaction between TR2 and TRIM28 is required for TRIM28 telomeric localization; a TRIM28 variant defective in orphan NR interaction fails to localize to telomeres and cannot promote H3K9me3 or ALT phenotypes.\",\n      \"method\": \"Co-IP, ChIP, telomere-specific assays (C-circles, APBs), TRIM28 interaction-defective mutant, human fibroblast and ALT cancer cell lines\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP + ChIP + mutant rescue; preprint, single lab\",\n      \"pmids\": [\"bio_10.1101_2025.06.16.658187\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"NR2C1 (TR2) is an orphan nuclear receptor that binds AGGTCA direct repeat elements as homodimers or TR2/TR4 heterodimers to repress or activate target genes (including embryonic/fetal β-globin, GATA1, Oct4, RARβ2, and others) through ligand-independent mechanisms involving post-translational modifications (PKC-mediated phosphorylation at Ser-185/Ser-568/Thr-210, SUMOylation at Lys-238, ubiquitination) that regulate its subcellular partitioning to PML nuclear bodies, protein stability, and differential recruitment of coactivators (PCAF, p300) versus corepressors (RIP140, HDAC3, HDAC4, NuRD, DNMT1, LSD1/CoREST, TIF1β, TRIM28), thereby controlling globin gene switching in erythropoiesis, stem cell pluripotency (Oct4/Nanog), retinal development, and alternative telomere lengthening.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"NR2C1 (TR2) is an orphan nuclear receptor that functions as a ligand-independent transcriptional regulator of globin gene switching, stem cell pluripotency, retinal development, and other developmental programs. TR2 binds AGGTCA direct repeat elements (DR1–DR5) as homodimers or as TR2/TR4 heterodimers, recruiting epigenetic corepressor complexes (DNMT1, NuRD, LSD1/CoREST, HDAC3, HDAC4, RIP140, TIF1β) to silence embryonic and fetal β-type globin genes in definitive erythroid cells, while conditional loss of both TR2 and TR4 reactivates embryonic globin expression and impairs terminal erythroid maturation [PMID:12093744, PMID:25561507, PMID:21670149]. Post-translational modifications act as a molecular switch controlling TR2 output: PKC-mediated phosphorylation at Ser-185 promotes DNA binding and PCAF coactivator recruitment for target gene activation, whereas ERK2-mediated phosphorylation at Thr-210 drives TR2 into PML nuclear bodies where SUMOylation at Lys-238 triggers coactivator-to-corepressor exchange (PCAF→RIP140), converting TR2 from an activator to a repressor of Oct4 [PMID:16317770, PMID:18682553, PMID:17187077]. Nr2c1 loss-of-function in mice causes severe visual deficits with disrupted early retinal cell patterning, establishing a non-redundant role in retinal development [PMID:28551284].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"The molecular identity of TR2 as an orphan nuclear receptor was established, revealing a steroid receptor superfamily member with no known ligand, thereby opening the question of what biological functions it serves.\",\n      \"evidence\": \"cDNA cloning from human testis libraries with sequence analysis and in vitro translation\",\n      \"pmids\": [\"2597158\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No endogenous ligand identified\", \"No target genes or biological function known\", \"Expression pattern beyond testis not characterized\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"The DNA-binding specificity and dual transcriptional activity of TR2 were defined: it binds AGGTCA direct repeats (DR1–DR5) as homodimers via its ligand-binding domain, functioning as either a repressor (competing with RAR/RXR at DR5) or an activator (at DR4 sites), with the full-length LBD required for DNA binding and opposing activities of truncated isoforms.\",\n      \"evidence\": \"EMSA with Kd measurements, CAT/luciferase reporter assays, isoform comparison, domain mutagenesis across multiple target elements (CRBPII, RARβ, CRABP-I, aldolase A)\",\n      \"pmids\": [\"8530418\", \"9369481\", \"9071982\", \"7890658\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous target genes in vivo not yet identified\", \"Mechanism of context-dependent activation vs. repression unclear\", \"In vivo relevance of homodimer binding not established\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"The corepressor and dimerization architecture of TR2 was resolved: RIP140 was identified as the first corepressor binding TR2 via LXXLL motifs at the AF-2 domain; TR2/TR4 heterodimers were shown to form preferentially and repress more strongly than homodimers; and a transferable silencing domain (DEF segment) with critical leucine residues on the dimer interface was mapped.\",\n      \"evidence\": \"Yeast two-hybrid, co-IP, GFP localization, pull-down assays, mammalian two-hybrid, EMSA, domain mutagenesis, reporter assays\",\n      \"pmids\": [\"9774688\", \"9737983\", \"9660764\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TR2 chooses between repression and activation at different promoters unknown\", \"No chromatin-level evidence for corepressor action\", \"Physiological significance of TR2/TR4 heterodimer not established in vivo\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"The nuclear localization mechanism of TR2 was mapped to a 20-amino-acid constitutive NLS within the second zinc finger of the DNA-binding domain, and upstream regulation by p53 (repression upon ionizing radiation) and CNTF signaling was established.\",\n      \"evidence\": \"GFP fusion imaging with deletion mapping; radiation treatment with Northern blot and p53 epistasis; RT-PCR and reporter assays for CNTF pathway\",\n      \"pmids\": [\"9795341\", \"8663350\", \"9694834\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological consequence of p53-mediated TR2 repression unclear\", \"CNTF pathway connection not validated in vivo\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"TR2-mediated repression was linked to histone deacetylation: HDAC3 (class I) and HDAC4 (class II) directly interact with TR2 through its DNA-binding domain, and HDAC inhibitor TSA relieves TR2 repression, establishing an epigenetic mechanism for TR2 silencing activity.\",\n      \"evidence\": \"Co-IP, GST pull-down, far Western, deacetylase activity assay, reporter assays with TSA\",\n      \"pmids\": [\"11463856\", \"14521922\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which endogenous target genes are repressed via HDAC recruitment unknown\", \"Relative contribution of HDAC3 vs. HDAC4 not resolved\", \"No in vivo chromatin-level evidence at this stage\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"The physiological target of TR2/TR4 was identified: the DRED complex (~540 kDa TR2/TR4 heterodimer) binds DR1 sites in embryonic ε-globin and fetal γ-globin promoters, and an HPFH mutation disrupts this binding, directly implicating TR2/TR4 in developmental globin gene silencing. Separately, TR2 was shown to suppress estrogen receptor signaling through direct heterodimerization.\",\n      \"evidence\": \"Biochemical purification with mass spectrometry, EMSA with HPFH mutant DR1, transgenic mouse overexpression; GST pull-down and two-hybrid for ER interaction\",\n      \"pmids\": [\"12093744\", \"12093804\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TR2/TR4 distinguish embryonic from adult globin promoters not explained\", \"Corepressor complexes on globin promoters not yet identified\", \"ER interaction not validated in primary tissues\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Post-translational modifications were shown to act as a molecular switch controlling TR2 output: PKC phosphorylation at Ser-185 (DBD) enhances DNA binding and PCAF coactivator recruitment, while SUMOylation at Lys-238 triggers release from PML nuclear bodies and coactivator-to-corepressor (PCAF→RIP140) exchange, converting TR2 from an Oct4 activator to a repressor.\",\n      \"evidence\": \"LC-ESI-MS/MS phosphosite identification, site-directed mutagenesis, EMSA, co-IP, GFP live imaging at PML bodies, ChIP, SUMOylation assays\",\n      \"pmids\": [\"16317770\", \"16130175\", \"17187077\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How SUMOylation physically displaces TR2 from PML bodies not resolved\", \"Whether the PKC and SUMO modifications are coordinated or independent unclear\", \"In vivo relevance for stem cell differentiation not yet demonstrated genetically\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"A complete atRA-triggered signaling cascade was delineated: atRA activates MEK/ERK2, which phosphorylates TR2 at Thr-210; phospho-TR2 is chaperoned to PML bodies by HDAC3 (independent of its deacetylase activity), undergoes SUMOylation, and switches from Oct4 activator to repressor, providing an integrated mechanism for retinoic acid-induced loss of pluripotency.\",\n      \"evidence\": \"Phosphorylation assays with Thr-210 mutagenesis, MEK/ERK inhibitors, co-IP, confocal microscopy, deacetylase-dead HDAC3 mutant rescue\",\n      \"pmids\": [\"18682553\", \"19204783\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this cascade operates in embryonic stem cells in vivo not shown\", \"Structural basis for HDAC3 chaperone function unknown\", \"Fate of TR2 after PML body targeting (degradation vs. stable repression) unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"The full corepressor landscape at globin promoters was defined: TR2/TR4 recruit DNMT1, NuRD, LSD1/CoREST, HDAC3, and TIF1β specifically to embryonic β-globin promoters in adult erythroid cells; during terminal differentiation these corepressors remain at silenced embryonic promoters but dissociate from adult promoters, explaining developmental stage-specific silencing.\",\n      \"evidence\": \"Biotin-tagged purification with mass spectrometry, co-IP, ChIP comparing differentiated vs. undifferentiated erythroid cells\",\n      \"pmids\": [\"21670149\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How promoter-specific retention of corepressors is achieved unknown\", \"Which corepressor is rate-limiting for silencing not determined\", \"No evidence for direct DNA methylation by DNMT1 at these loci shown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Genetic proof that TR2/TR4 are required for embryonic globin silencing in adult erythropoiesis was obtained: compound conditional knockout of Tr2 and Tr4 in adult bone marrow reactivated embryonic εy and βh1 globins, abolished TR2/TR4 and corepressor occupancy at those promoters, and impaired terminal erythroid maturation.\",\n      \"evidence\": \"Conditional double knockout mouse, ChIP, RT-PCR, flow cytometry, in vitro bone marrow differentiation\",\n      \"pmids\": [\"25561507\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TR2/TR4 loss can reactivate human fetal γ-globin therapeutically not tested\", \"Mechanism of erythroid maturation defect beyond globin regulation not explored\", \"Redundancy between TR2 and TR4 at individual promoters not fully parsed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"A non-redundant role for NR2C1 in retinal development was established: Nr2c1 knockout mice exhibit severe vision deficits with disrupted early retinal progenitor patterning, including altered amacrine cell displacement and cone photoreceptor topography, with ChIP showing TR2 directly regulates early retinal transcription factors including Satb2.\",\n      \"evidence\": \"Nr2c1 knockout mouse, electroretinography, histology, immunofluorescence, ChIP\",\n      \"pmids\": [\"28551284\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TR2 functions as activator or repressor of retinal target genes not fully resolved\", \"Retinal phenotype relationship to TR2/TR4 heterodimer function not tested\", \"Human retinal disease association not established\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"TR2 was implicated in alternative lengthening of telomeres (ALT) through recruitment of TRIM28/TIF1β to telomeric chromatin, promoting H3K9me3 heterochromatin formation; a TRIM28 variant unable to interact with orphan nuclear receptors failed to localize to telomeres or promote ALT phenotypes.\",\n      \"evidence\": \"Co-IP, ChIP, C-circle and APB assays, TRIM28 interaction-defective mutant in ALT cancer cell lines (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.06.16.658187\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint not yet peer-reviewed\", \"Relative contribution of TR2 vs. other orphan NRs (COUP-TFs, TR4) at telomeres not parsed\", \"Whether TR2 is required for ALT in vivo not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: whether TR2 has an endogenous ligand, the structural basis for context-dependent switching between activation and repression, whether TR2/TR4-targeted therapies can reactivate fetal hemoglobin for sickle cell disease treatment, and how TR2's roles in retinal development, pluripotency, and telomere biology are integrated at the organismal level.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No endogenous ligand identified despite >35 years of study\", \"No crystal structure of full-length TR2 or TR2/TR4 heterodimer available\", \"Therapeutic targeting of TR2/TR4 for hemoglobin disorders not validated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [1, 2, 3, 4, 7, 14, 17, 24]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 5, 8, 14, 22, 24, 25, 28]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [16, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [10, 22, 26, 27]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [22, 26, 27]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [15, 18, 28]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 5, 8, 14, 24, 25, 28]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [25, 30]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [20, 21, 22, 26]}\n    ],\n    \"complexes\": [\n      \"DRED (TR2/TR4 heterodimer)\",\n      \"NuRD\",\n      \"LSD1/CoREST\"\n    ],\n    \"partners\": [\n      \"NR2C2\",\n      \"RIP140\",\n      \"HDAC3\",\n      \"HDAC4\",\n      \"PCAF\",\n      \"TRIM28\",\n      \"DNMT1\",\n      \"PML\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}